Background: To estimate the value of treatments in multiple sclerosis (MS)–where lifetime
costs and outcomes cannot be observed–outcome data have to be combined with cost data …

Aims: The aim of this study was to quantify how multiple sclerosis (MS) phenotypes differ
from each other in respect of costs and quality-of-life. Materials and methods: The study is …

Background Estimating direct healthcare costs of patients with multiple sclerosis (MS) and
identifying risk factors of high costs including relapse are important drivers of public health …

Aims: Multiple sclerosis treatment strategies are changing in the Czech Republic. According
to data from 2013-2021, the proportion of patients starting high-efficacy disease-modifying …

Background Multiple Sclerosis (MS) is a chronic inflammatory, immune mediated disease of
the central nervous system, with Relapsing Remitting MS (RRMS) being the most common …

Background: A diagnosis of multiple sclerosis (MS) can be categorized based on its disease
course into the following phenotypes: relapsing-remitting MS (RRMS), primary progressive …

Background Current guidelines recommend regular neurological MS care in persons
diagnosed with MS, but little is known about implementation of this recommendation or …

Aims: To estimate costs of multiple sclerosis (MS) in a German cohort according to severity
of the disease and clinical symptoms. Methods: 144 patients were recruited from an MS …

Objective: Although multiple sclerosis (MS) is one of the most common causes of non-
traumatic disability among young adults, no published data on its economic and health …

Introduction The severity of relapses varies in multiple sclerosis (MS) and may lead to a
differential cost burden. This study aimed to characterize the direct healthcare costs …